RU2491084C2 - Способ улучшения терапевтической эффективности куркуминоидов и их аналогов - Google Patents
Способ улучшения терапевтической эффективности куркуминоидов и их аналогов Download PDFInfo
- Publication number
- RU2491084C2 RU2491084C2 RU2010130419/15A RU2010130419A RU2491084C2 RU 2491084 C2 RU2491084 C2 RU 2491084C2 RU 2010130419/15 A RU2010130419/15 A RU 2010130419/15A RU 2010130419 A RU2010130419 A RU 2010130419A RU 2491084 C2 RU2491084 C2 RU 2491084C2
- Authority
- RU
- Russia
- Prior art keywords
- curcumin
- psoriasis
- dose
- curcuminoids
- radiation
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 17
- 230000001225 therapeutic effect Effects 0.000 title abstract description 14
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 76
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 47
- 239000004148 curcumin Substances 0.000 claims abstract description 37
- 235000012754 curcumin Nutrition 0.000 claims abstract description 37
- 229940109262 curcumin Drugs 0.000 claims abstract description 37
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 37
- 238000011282 treatment Methods 0.000 claims abstract description 36
- 206010047642 Vitiligo Diseases 0.000 claims abstract description 14
- 208000000069 hyperpigmentation Diseases 0.000 claims abstract description 9
- 230000003810 hyperpigmentation Effects 0.000 claims abstract description 9
- 239000002537 cosmetic Substances 0.000 claims abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 230000005855 radiation Effects 0.000 claims description 38
- 239000003814 drug Substances 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 8
- 230000001965 increasing effect Effects 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract 1
- 238000001126 phototherapy Methods 0.000 description 29
- 230000009467 reduction Effects 0.000 description 14
- 244000163122 Curcuma domestica Species 0.000 description 12
- 235000003373 curcuma longa Nutrition 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000012675 alcoholic extract Substances 0.000 description 9
- 208000012641 Pigmentation disease Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000019612 pigmentation Effects 0.000 description 8
- 238000007910 systemic administration Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 7
- 229930153442 Curcuminoid Natural products 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 235000003392 Curcuma domestica Nutrition 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000009291 secondary effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 235000013976 turmeric Nutrition 0.000 description 5
- 235000020240 turmeric extract Nutrition 0.000 description 5
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229960002749 aminolevulinic acid Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- 208000022120 Jeavons syndrome Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229960001271 desloratadine Drugs 0.000 description 3
- 229960000284 efalizumab Drugs 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940052016 turmeric extract Drugs 0.000 description 3
- 239000008513 turmeric extract Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000031709 Skin Manifestations Diseases 0.000 description 2
- 229930003537 Vitamin B3 Natural products 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- LBTVHXHERHESKG-UHFFFAOYSA-N tetrahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 LBTVHXHERHESKG-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 235000019160 vitamin B3 Nutrition 0.000 description 2
- 239000011708 vitamin B3 Substances 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 1
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 239000000399 hydroalcoholic extract Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000025402 neoplasm of esophagus Diseases 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Radiation-Therapy Devices (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/ES2007/000753 WO2009080842A1 (es) | 2007-12-21 | 2007-12-21 | Composiciones fotoprotectoras |
| ESPCT/ES2007/000753 | 2007-12-21 | ||
| EPEP08003253 | 2008-02-22 | ||
| EP08003253 | 2008-02-22 | ||
| EPEP08019146 | 2008-10-31 | ||
| EP08019146 | 2008-10-31 | ||
| PCT/ES2008/000787 WO2009080850A1 (es) | 2007-12-21 | 2008-12-19 | Método para aumentar la eficacia terapéutica de los curcuminoides y análogos. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010130419A RU2010130419A (ru) | 2012-01-27 |
| RU2491084C2 true RU2491084C2 (ru) | 2013-08-27 |
Family
ID=40800743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010130419/15A RU2491084C2 (ru) | 2007-12-21 | 2008-12-19 | Способ улучшения терапевтической эффективности куркуминоидов и их аналогов |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8748494B2 (enExample) |
| EP (1) | EP2236150B1 (enExample) |
| JP (1) | JP6062616B2 (enExample) |
| KR (1) | KR20100114498A (enExample) |
| CN (1) | CN101903034B (enExample) |
| AU (1) | AU2008341666B2 (enExample) |
| BR (1) | BRPI0819501A2 (enExample) |
| CA (1) | CA2708449C (enExample) |
| ES (1) | ES2739874T3 (enExample) |
| MX (1) | MX2010005441A (enExample) |
| RU (1) | RU2491084C2 (enExample) |
| WO (1) | WO2009080850A1 (enExample) |
| ZA (1) | ZA201004622B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12012501275A1 (en) | 2009-12-21 | 2017-07-26 | Colgate Palmolive Co | Kit containing photosensitizing dyes |
| KR101344303B1 (ko) * | 2011-10-07 | 2013-12-24 | 동성제약주식회사 | 표적 치료에 관한 종양에 선택성이 있는 콘쥬게이트 |
| US20130201574A1 (en) * | 2012-02-03 | 2013-08-08 | Satish Kumar GOPALAKRISHNAN | Phototherapy method and apparatus |
| EP2857379B1 (en) | 2012-05-08 | 2020-09-02 | Asac Compañía De Biotecnología E Investigación SA | Method for the synthesis of curcumin |
| CN103083289A (zh) * | 2013-01-25 | 2013-05-08 | 广东省中医院 | 姜黄素在制备治疗银屑病药物中的应用 |
| US20150065943A1 (en) * | 2013-08-27 | 2015-03-05 | Matthew DeBow | Method to Accelerate Healing |
| MY174568A (en) * | 2013-12-31 | 2020-04-27 | Sirim Berhad | A bioactive composition having natural uv photoprotective properties |
| CA2935865A1 (en) | 2014-01-10 | 2015-07-16 | Sebacia, Inc. | Treatment intervals for use of compositions comprising energy absorbing materials for dermatological applications |
| US10092550B2 (en) | 2014-10-21 | 2018-10-09 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof |
| US9907786B2 (en) | 2014-10-21 | 2018-03-06 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof |
| US20160106687A1 (en) | 2014-10-21 | 2016-04-21 | Life Plus, LLC | Human therapeutic agents |
| US10085951B2 (en) | 2014-12-11 | 2018-10-02 | Designs For Health, Inc. | Curcuminoid formulations and related methods of treatment |
| CN104814946A (zh) * | 2015-04-21 | 2015-08-05 | 中国科学院昆明动物研究所 | 姜黄素在制备治疗自身免疫疾病药物中的应用 |
| WO2018200786A1 (en) * | 2017-04-26 | 2018-11-01 | Yale University | Compositions and methods for treating vitiligo |
| US11484510B2 (en) * | 2017-08-28 | 2022-11-01 | Apirx Pharmaceutical Usa, Llc | Method to treat vitiligo |
| CN109364047A (zh) * | 2018-09-21 | 2019-02-22 | 天津中医药大学 | 四氢姜黄素在制备治疗白癜风药物或化妆品中的应用 |
| US12129265B2 (en) | 2020-07-21 | 2024-10-29 | Ankh Life Sciences Limited | Therapeutic agents and uses thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1133992A1 (en) * | 1999-09-23 | 2001-09-19 | ASAC Compania de Biotecnologia E Investigacion, S.A. | Novel pharmacological activities of curcuma longa extracts |
| WO2003039452A2 (en) * | 2001-11-06 | 2003-05-15 | The Quigley Corporation | Nutritional supplements and methods for prevention, reduction and treatment of radiation injury |
| RU2209098C1 (ru) * | 2002-11-28 | 2003-07-27 | Государственное учреждение "Центральный научно-исследовательский кожно-венерологический институт" | Способ лечения витилиго |
| RU2296389C2 (ru) * | 2003-01-21 | 2007-03-27 | Озрам Сильвания Инк. | Излучающая ультрафиолет люминофорная композиция и содержащая ее лампа для загара |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4137540A1 (de) * | 1991-11-14 | 1993-05-19 | Steigerwald Arzneimittelwerk | Verwendung von praeparaten der curcuma-pflanzen |
| US5925376C1 (en) | 1994-01-10 | 2001-03-20 | Madalene C Y Heng | Method for treating psoriasis using selected phosphorylase kinase inhibitor and additional compounds |
| US6440468B1 (en) * | 1994-08-03 | 2002-08-27 | A.S.A.C. Pharmaceutical International, A.I.E. | Method for obtaining apolar and polar extracts of curcuma and applications thereof |
| US5891924A (en) | 1996-09-26 | 1999-04-06 | Research Development Foundation | Curcumin (diferuloylmethane) inhibition of NFκB activation |
| US5897865A (en) * | 1997-06-30 | 1999-04-27 | Nguyen; Van Bich | Turmeric for treating skin disorders |
| WO2000002491A1 (en) * | 1998-07-09 | 2000-01-20 | Curelight Ltd. | Apparatus and method for efficient high energy photodynamic therapy of acne vulgaris and seborrhea |
| US20010051184A1 (en) * | 1999-05-20 | 2001-12-13 | Madalene C.Y. Heng | Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases |
| US6673843B2 (en) * | 1999-06-30 | 2004-01-06 | Emory University | Curcumin and curcuminoid inhibition of angiogenesis |
| US7220438B2 (en) * | 1999-09-23 | 2007-05-22 | Asac Compañia de Biotecnologia | Pharmacological activities of Curcuma longa extracts |
| DE10123926A1 (de) * | 2001-03-08 | 2002-09-19 | Optomed Optomedical Systems Gmbh | Bestrahlungsanordnung |
| IL148257A0 (en) * | 2001-12-06 | 2002-09-12 | Curelight Ltd | Phototherapy for psoriasis and other skin disorders |
| AU2003229923A1 (en) | 2002-04-16 | 2003-11-03 | Isis Innovation Limited | Curcumin for the prevention and/or treatment of tissue damage |
| US7556818B1 (en) * | 2003-05-07 | 2009-07-07 | Heng Madalene C Y | Composition for and method of treating psoriasis |
| US20070003582A1 (en) | 2003-11-25 | 2007-01-04 | Heng Madalene C | Medicine for the treatment of acne and for reversing the signs of age and sun damage and method for using same |
| US7067159B2 (en) | 2003-12-05 | 2006-06-27 | New Chapter, Inc. | Methods for treating prostate cancer with herbal compositions |
| EP1837030A1 (en) | 2006-03-09 | 2007-09-26 | INDENA S.p.A. | Phospholipid complexes of curcumin having improved bioavailability |
| US20080058426A1 (en) * | 2006-08-29 | 2008-03-06 | Muhammed Majeed | Composition and method for treating psoriasis |
-
2008
- 2008-12-19 CA CA2708449A patent/CA2708449C/en not_active Expired - Fee Related
- 2008-12-19 RU RU2010130419/15A patent/RU2491084C2/ru active
- 2008-12-19 ES ES08863766T patent/ES2739874T3/es active Active
- 2008-12-19 JP JP2010538803A patent/JP6062616B2/ja not_active Expired - Fee Related
- 2008-12-19 AU AU2008341666A patent/AU2008341666B2/en not_active Ceased
- 2008-12-19 EP EP08863766.5A patent/EP2236150B1/en active Active
- 2008-12-19 WO PCT/ES2008/000787 patent/WO2009080850A1/es not_active Ceased
- 2008-12-19 MX MX2010005441A patent/MX2010005441A/es active IP Right Grant
- 2008-12-19 BR BRPI0819501-3A patent/BRPI0819501A2/pt not_active Application Discontinuation
- 2008-12-19 KR KR1020107016023A patent/KR20100114498A/ko not_active Ceased
- 2008-12-19 CN CN2008801217511A patent/CN101903034B/zh not_active Expired - Fee Related
-
2010
- 2010-06-09 US US12/797,059 patent/US8748494B2/en not_active Expired - Fee Related
- 2010-06-30 ZA ZA2010/04622A patent/ZA201004622B/en unknown
-
2014
- 2014-05-22 US US14/284,475 patent/US9211270B2/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1133992A1 (en) * | 1999-09-23 | 2001-09-19 | ASAC Compania de Biotecnologia E Investigacion, S.A. | Novel pharmacological activities of curcuma longa extracts |
| WO2003039452A2 (en) * | 2001-11-06 | 2003-05-15 | The Quigley Corporation | Nutritional supplements and methods for prevention, reduction and treatment of radiation injury |
| RU2209098C1 (ru) * | 2002-11-28 | 2003-07-27 | Государственное учреждение "Центральный научно-исследовательский кожно-венерологический институт" | Способ лечения витилиго |
| RU2296389C2 (ru) * | 2003-01-21 | 2007-03-27 | Озрам Сильвания Инк. | Излучающая ультрафиолет люминофорная композиция и содержащая ее лампа для загара |
Non-Patent Citations (1)
| Title |
|---|
| Jadranka Dujic et all. Low Concentrations of Curcumin Induce Growth Arrest and Apoptisis in Skin Keratinocytes Only in Combination with UVA or Visible Light // Journal of Investigate Dermatology (2007) 127, p.1992-2000, published online 05.04.2007. * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100114498A (ko) | 2010-10-25 |
| AU2008341666B2 (en) | 2013-10-03 |
| CA2708449C (en) | 2020-11-24 |
| AU2008341666A1 (en) | 2009-07-02 |
| JP6062616B2 (ja) | 2017-01-18 |
| RU2010130419A (ru) | 2012-01-27 |
| ES2739874T3 (es) | 2020-02-04 |
| WO2009080850A1 (es) | 2009-07-02 |
| US9211270B2 (en) | 2015-12-15 |
| EP2236150B1 (en) | 2019-05-29 |
| CN101903034B (zh) | 2013-07-31 |
| US8748494B2 (en) | 2014-06-10 |
| EP2236150A4 (en) | 2012-02-29 |
| BRPI0819501A2 (pt) | 2015-05-26 |
| MX2010005441A (es) | 2010-09-03 |
| CA2708449A1 (en) | 2009-07-02 |
| US20100298444A1 (en) | 2010-11-25 |
| JP2011506019A (ja) | 2011-03-03 |
| US20140257170A1 (en) | 2014-09-11 |
| CN101903034A (zh) | 2010-12-01 |
| ZA201004622B (en) | 2011-03-30 |
| EP2236150A1 (en) | 2010-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2491084C2 (ru) | Способ улучшения терапевтической эффективности куркуминоидов и их аналогов | |
| Filonenko et al. | 5-Aminolevulinic acid in intraoperative photodynamic therapy of bladder cancer (results of multicenter trial) | |
| Maytin et al. | Blue light versus red light for photodynamic therapy of basal cell carcinoma in patients with Gorlin syndrome: a bilaterally controlled comparison study | |
| US20220354952A1 (en) | Photodynamic therapy method for skin disorders | |
| Yu et al. | Photodynamic therapy outcome for oral verrucous hyperplasia depends on the clinical appearance, size, color, epithelial dysplasia, and surface keratin thickness of the lesion | |
| KR20140076641A (ko) | 아미노레불린산 및 그것의 유도체의 용도 | |
| US20230131170A1 (en) | Topical compositions and methods for photodynamic therapy | |
| EP3082789A1 (en) | Pulse photodynamic treatment of skin conditions | |
| Chen et al. | Topical 5-aminolevulinic acid-mediated photodynamic therapy for oral verrucous hyperplasia, oral leukoplakia and oral erythroleukoplakia | |
| RU2161053C1 (ru) | Способ фотодинамической терапии больных злокачественными опухолями | |
| Neittaanmäki-Perttu et al. | Safety of Novel Amino-5-laevulinate Photosensitizer Precursors in Photodynamic Therapy on Healthy Human Skin | |
| Vakulovskaya | Photodynamic therapy and fluorescent diagnostics of head and neck cancer with second-generation photosensitizers | |
| US20220296918A1 (en) | Method for targeted treating dermatoses | |
| Yu | Photodynamic therapy: the light treatment for cutaneous non-melanoma malignancies | |
| US20220296919A1 (en) | Method for targeted treating dermatoses | |
| Bordoloi et al. | Efficacy of Aminolevulinic Acid Mediated Photodynamic Therapy in the Treatment of Oral Premalignant Lesions: A Systematic Review | |
| Vakulovskaya et al. | Photodynamic therapy and fluorescent diagnostics of skin cancer with radochlorine and photosense: comparing efficacy and toxicity | |
| WO2009080842A1 (es) | Composiciones fotoprotectoras | |
| ES1073588U (es) | Equipo para fototerapia. | |
| Sheleg et al. | Photodynamic therapy with chlorin e6 for skin metastases of melanoma | |
| Dupont | FC039 Incidence of psoriatic arthropathy | |
| Fink-Puches et al. | Topical sensitization—oncologic indications-others (lymphoma) |